India’s seven-day average of new COVID-19 cases is at a record high of more than 390,000. The World Health Organization has labeled a variant circulating in the country as a global risk. (Reuters)

The Food and Drug Administration has authorized Pfizer’s COVID-19 vaccine for use in children aged 12 to 15. The approval will likely jump-start a vaccination effort designed to reach high schoolers prior to the next school year. (Politico)

In a new study, an experimental gene therapy that uses the AIDS virus has shown promise in treating children with “bubble baby” disease. Using a disabled AIDS virus, scientists inserted a healthy version of the gene that affected children needed in order to develop a working immune system. (STAT)

Novavax announced it will likely not seek emergency use authorization for its COVID-19 vaccine until July, due to regulatory issues around manufacturing. The federal government is funding the effort with $1.6 billion. (The Washington Post)

Ginkgo Bioworks announced it will go public and merge with Soaring Eagle Acquisition Corp. The SPAC has brought in investors like Cathie Wood of Ark Invest and the company is now valued at $15 billion. (Endpoints News)